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It is generally considered that most cancers arise following the accumulation of several genetic events and that as a
consequence its incidence increases with age. We report a cytogenetic subgroup of acute myeloid leukaemia whose incidence
is independent of age. This observation indicates that acute myeloid leukaemia can develop via multiple pathways, and
underlines the importance of cytogenetics in understanding this disease.
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Cytogenetically-deﬁned subtypes of acute myeloid leukaemia
(AML) have distinct pathological and clinical features. In addition,
many chromosomal abnormalities are important indicators of
prognosis and are used to determine treatment strategies (Wheatley
et al, 1999). Although, the link between cytogenetics and aetiology
in AML remains uncertain some supporting evidence does exist.
The main two cytogenetic subtypes seen in therapy-related leukae-
mia – 11q23 abnormalities and loss of 5q/7q – are closely
associated with prior therapy with DNA topoisomerase II inhibi-
tors and alkylating agents, respectively (Felix, 1998).
Unfortunately, the results from the few studies investigating a link
between smoking, alcohol, organic chemicals, pesticides and cyto-
genetic subgroups have been less convincing and are often
contradictory (Crane et al, 1989; Sandler et al, 1993; Crane et al,
1996).
We, and others, have reported distinct age distribution proﬁles
for AML patients with certain chromosomal abnormalities
(IWCL4, 1984; Keating et al, 1987; Mauritzson et al, 1999;
Moorman et al, 2001). Age is an important factor to be consid-
ered when investigating the aetiology of a disease as it can
provide clues to its pathogenesis. The exponential increase in
cancer incidence with age was fundamental to the development
of the multi-stage theory of carcinogenesis because the probabil-
ity of accumulating the full set of mutations required to effect
malignant transformation increases with time (Armitage and
Doll, 1954). In order to examine more closely the relationship
between age and cytogenetics we have estimated the age-speciﬁc
incidences rates of the principal cytogenetic subgroups seen in
AML.
PATIENTS AND METHODS
This study was based on cases with de novo AML recruited to a
population-based case–control study of acute leukaemia (Kane et
al, 1999). Brieﬂy, the study ascertained adults (16–69 years old)
diagnosed with acute leukaemia over a 5-year period in two regions
of England. The Northern region consisted of the former Yorkshire
Regional Health Authority and the counties of Lancashire and
Cumbria. The Southern region was deﬁned as the then regional
health authorities of the South West and Wessex. Case ascertain-
ment started in April 1991 and ended in March 1996 in the
Northern region and in December 1996 in the Southern region.
The current analysis has been restricted to patients with a patholo-
gically conﬁrmed diagnosis of de novo AML.
Diagnostic cytogenetic data were collected from regional labora-
tories and classiﬁed as previously described (Moorman et al, 2001).
Cytogenetic analysis was considered successful if an abnormal clone
or 10 normal metaphases were observed, otherwise it was classiﬁed
as failed. Successful cases were classiﬁed hierarchically according to
the type of the primary chromosomal abnormality into one of four
karyotype groups: (1) translocations (including inversions and
insertions); (2) deletions (including monosomies); (3) trisomies
(including duplications); and (4) no abnormality detected
(NAD). In addition, those cases with a chromosomal abnormality
were also classiﬁed hierarchically according to the presence of the
ﬁve most frequently observed speciﬁc aberrations:
t(15;17)(q22;q12), t(8;21)(q22;q22), inv(16)(p13q22), del(5q)/75/
del(7q)/77 and +8. Other abnormalities occurred too infrequently
to be considered separately and were therefore grouped together
under the ‘other’ heading.
The population resident within the study area was assumed to
be stable during the study period and was estimated using 1991
UK census data, obtained from Manchester Information and Asso-
ciated Services at the University of Manchester. Using age-speciﬁc
population ﬁgures, the number of person-years in each region
was calculated and summed to give the number of person-years
in each age group. The study population was estimated at 7.8
million people, giving a total of 42.5 million person-years. Age-
speciﬁc incidence rates were estimated (per million) by dividing
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person-years at risk. As AML is a rare disease the number of cases
were not subtracted from the total.
RESULTS
Of the 779 cases diagnosed with de novo AML 593 (76%) had a
cytogenetic result, while 34 (4%) failed and 152 (20%) were not
tested. Overall, the incidence of de novo AML increased with
age – rising from 510 per million among those aged 16–29 years
to 440 per million among those aged 60–69 years (Table 1). This
pattern was observed for some but not all the cytogenetic
subgroups investigated (Table 1, Figure 1). For example, the age-
speciﬁc incidence rates for the deletion and normal karyotype
groups as well as the 5q/7q group rose sharply with increasing
age especially among the older two age groups. Although the inci-
dence rates for the remaining three subgroups – trisomy, +8 and
‘other’ – also increased with age the rise was not as sharp and was
conﬁned to the oldest age group. The most notable exceptions to
this pattern were the translocation karyotype group and the three
speciﬁc translocations – t(15;17), t(8;21) and inv(16), whose inci-
dence rates remained static across the different age groups.
DISCUSSION
Our ﬁndings suggest that while the overall incidence of AML
increases with age, the incidence of ‘translocation-positive’
AML does not increase with age. A recent study which showed
that the incidence rate of acute promyelocytic leukaemia (which
is synonymous with t(15;17)) is constant with age supports
these ﬁndings (Vickers et al, 2000). It is generally assumed that
cancer incidence increases with age because of the time required
to accumulate the requisite number of mutations to effect
malignant transformation. Armitage and Doll (1954) estimated
that six or seven mutations would be required to produce the
age distributions observed in their study. The age distribution
of ‘translocation-positive’ AML clearly does not ﬁt this model
as its incidence is roughly constant between the ages of 16
and 69. Although we cannot calculate the actual number of
mutations required to produce ‘translocation-positive’ AML
from such an observation, it is reasonable to conclude that only
one ‘rate-limiting’ step is required. Moreover, we can infer that
there are at least two separate aetiological pathways which can
give rise to AML. Therefore, studies investigating the causes
AML should, where possible, assess the impact of cytogenetics
on their ﬁndings.
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Figure 1 Age-speciﬁc incidence rates (per million) for de novo acute
myeloid leukaemia by karyotype group.
Table 1 Number of cases and age-speciﬁc incidence rates (per million) for de novo acute myeloid
leukaemia stratiﬁed by cytogenetics
Cytogenetic Number Incidence
Incidence rates by age at diagnosis (years)
group of cases rate 16–19 20–29 30–39 40–49 50–59 60–69
Cytogenetic investigation
Total cases 779 18.32 6.69 9.71 11.82 14.10 24.00 43.79
Successful cases 593 13.94 6.08 8.49 9.55 11.51 17.55 30.35
Failed 34 0.80 0.00 0.33 0.12 0.47 1.95 1.96
Not tested 152 3.57 0.61 0.88 2.15 2.11 4.50 11.48
Karyotype group
Successful cases 593 13.94 6.08 8.49 9.55 11.51 17.55 30.35
Translocation 179 4.21 2.13 4.52 4.30 4.23 4.65 4.23
Deletion 106 2.49 0.91 0.55 1.19 1.17 3.60 8.15
Trisomy 66 1.55 0.61 1.10 0.84 1.41 1.80 3.47
NAD 242 5.69 2.43 2.32 3.22 4.70 7.50 14.50
Chromosomal abnormality
Abnormal cases 351 8.25 3.65 6.18 6.33 6.81 10.05 15.86
t(15;17) 74 1.74 0.91 1.88 1.67 1.76 2.25 1.51
t(8;21) 34 0.80 0.30 1.10 0.95 0.59 0.60 0.91
inv(16) 27 0.63 0.30 0.77 0.36 0.82 0.90 0.45
5q/7q 67 1.58 0.30 0.22 0.72 0.82 2.10 5.59
+8 40 0.94 0.61 0.66 0.72 0.59 1.20 1.96
Other 109 2.56 1.22 1.54 1.91 2.23 3.00 5.44
NAD=No abnormality detected; 5q/7q, deletion or monosomy of 5q or 7q.
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